Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration

Neurobiology of Disease

Volumn 49, Issue 1, 2013, Pages 159-168

  Choi, Dong Young ^a,b   Lee, Myung Koo ^b   Hong, Jin Tae ^b  

^a Yeungnam University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Astrocyte; C C chemokine receptor 5; Dopamine; Monoamine oxidase; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CHEMOKINE RECEPTOR CCR5; MITOGEN ACTIVATED PROTEIN KINASE P38; TYROSINE 3 MONOOXYGENASE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); CCR5 PROTEIN, MOUSE; HOMOVANILLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; GLIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CORPUS STRIATUM; DEFICIENCY; DEGENERATIVE DISEASE; DISEASE MODEL; GENETICS; INTOXICATION; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HOMOVANILLIC ACID; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOAMINE OXIDASE; MOTOR ACTIVITY; MPTP POISONING; NEURODEGENERATIVE DISEASES; NEUROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CCR5; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84866540147     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.08.001     Document Type: Article

References (47)

1. Aarum J., et al. Migration and differentiation of neural precursor cells can be directed by microglia. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15983-15988.
2. Alper G., et al. MAO inhibitors and oxidant stress in aging brain tissue. Eur. Neuropsychopharmacol. 1999, 9:247-252.
3. Asensio V.C., Campbell I.L. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 1999, 22:504-512.
4. Betarbet R., et al. Animal models of Parkinson's disease. Bioessays 2002, 24:308-318.
5. Cartier L., et al. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res. Brain Res. Rev. 2005, 48:16-42.
6. Choi D.Y., et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 2009, 4:e5482.
7. Choi D.Y., et al. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. Neurobiol. Aging 2010, 31:1649-1653.
8. Choi D.Y., et al. Obovatol improves cognitive functions in animal models for Alzheimer's disease. J. Neurochem. 2012, 120:1048-1059.
9. De Zutter G.S., Davis R.J. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6168-6173.
10. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
11. Di Monte D.A., et al. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology 1996, 17:697-703.
12. Dong J., Xiong H. Human immunodeficiency virus type 1 gp120 inhibits long-term potentiation via chemokine receptor CXCR4 in rat hippocampal slices. J. Neurosci. Res. 2006, 83:489-496.
13. Fernagut P.O., et al. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 2002, 113:123-130.
14. Fowler C.J., et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm. 1980, 49:1-20.
15. Gade-Andavolu R., et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet. Med. 2004, 6:126-131.
16. Gamo K., et al. G-protein-coupled receptor screen reveals a role for chemokine receptor CCR5 in suppressing microglial neurotoxicity. J. Neurosci. 2008, 28:11980-11988.
17. Gulyas B., et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem. Int. 2011, 58:60-68.
18. Guyon A., et al. Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience 2009, 162:1072-1080.
19. Heikkila R.E., et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985, 116:313-317.
20. Huerta C., et al. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci. Lett. 2004, 370:151-154.
21. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
22. Kim W.G., et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20:6309-6316.
23. Kohutnicka M., et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998, 39:167-180.
24. Langston J.W., et al. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984, 225:1480-1482.
25. Lee Y.K., et al. CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol. Learn. Mem. 2009, 92:356-363.
26. Lu M., et al. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7090-7095.
27. Ma Q., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9448-9453.
28. Mallajosyula J.K., et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 2008, 3:e1616.
29. McMahon S.B., Malcangio M. Current challenges in glia-pain biology. Neuron 2009, 64:46-54.
30. Meucci O., et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14500-14505.
31. Oh S.B., et al. Regulation of calcium currents by chemokines and their receptors. J. Neuroimmunol. 2002, 123:66-75.
32. Okuda K., et al. Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo. Biol. Pharm. Bull. 2006, 29:1401-1403.
33. Park M.H., et al. Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation. Exp. Cell Res. 2009, 315:2715-2726.
34. Rentzos M., et al. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol. Scand. 2007, 116:374-379.
35. Saura J., et al. Age-related changes on MAO in Bl/C57 mouse tissues: a quantitative radioautographic study. J. Neural Transm. Suppl. 1994, 41:89-94.
36. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:57-66.
37. Song H., et al. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002, 417:39-44.
38. Sorce S., et al. Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5. Br. J. Pharmacol. 2010, 160:311-321.
39. Sorce S., et al. The chemokine receptor CCR5 in the central nervous system. Prog. Neurobiol. 2011, 93:297-311.
40. Stumm R.K., et al. CXCR4 regulates interneuron migration in the developing neocortex. J. Neurosci. 2003, 23:5123-5130.
41. Takada M., et al. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. Brain Res. 1990, 509:55-61.
42. Vijitruth R., et al. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2006, 3:6.
43. Westmoreland S.V., et al. Developmental expression patterns of CCR5 and CXCR4 in the rhesus macaque brain. J. Neuroimmunol. 2002, 122:146-158.
44. Wong W.K., et al. Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J. Biol. Chem. 2002, 277:22222-22230.
45. Wu D.C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
46. Youdim M.B., et al. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7:295-309.
47. Zou Y.R., et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.